Ligand Pharmaceuticals Inc LGND:NASDAQ

Last Price$84.29Cboe Real-Time Last Sale as of 12:40PM ET 4/09/20
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+1.28(1.54%)
Bid (Size)$83.70 (55)
Ask (Size)$84.69 (8)
Day Low / High$82.57 - 87.90
Volume186.3 K
 

View Biotechnology IndustryPeer Comparison as of 04/09/2020

 

Ligand Pharmaceuticals Inc ( NASDAQ )

Price: $84.29
Change: +1.28 (1.54%)
Volume: 186.3 K
12:40PM ET 4/09/2020
 
 

Luminex Corp ( NASDAQ )

Price: $28.03
Change: -1.66 (5.59%)
Volume: 183.1 K
12:40PM ET 4/09/2020
 
 

Karyopharm Therapeutics Inc ( NASDAQ )

Price: $20.75
Change: +1.47 (7.62%)
Volume: 907.1 K
12:35PM ET 4/09/2020
 
 

Dicerna Pharmaceuticals Inc ( NASDAQ )

Price: $19.85
Change: +0.85 (4.47%)
Volume: 150.9 K
12:36PM ET 4/09/2020
 
 

Heron Therapeutics Inc ( NASDAQ )

Price: $14.44
Change: +0.47 (3.36%)
Volume: 322.4 K
12:40PM ET 4/09/2020
 

Read more news Recent News

Analyst Actions: HC Wainwright Lowers Ligand Pharmaceuticals' Price Target to $229 From $237, Reiterates Buy Rating
12:26PM ET 4/08/2020 MT Newswires

Ligand Pharmaceuticals (LGND) has an average analyst rating of buy, with an average price target of $163. Price: 81.14, Change: +2.91, Percent Change:...

Consensus for Ligand Pharmaceuticals Q1 and Full Year Earnings Increased
9:35AM ET 4/03/2020 MT Newswires

The Q1 and 2020 forecasted earnings estimates for Ligand Pharmaceuticals Inc's (NASDAQ:LGND, Recent Price: 71.95) for the quarter ending March 31, 2020 and...

--Analyst Actions: Argus Research Downgrades Ligand Pharmaceuticals to Hold From Buy
12:32PM ET 3/24/2020 MT Newswires

Price: 74.39, Change: +3.85, Percent Change: +5.45 ...

Analyst Actions: Guggenheim Initiates Coverage on Ligand Pharmaceuticals With Neutral Rating
8:52AM ET 3/10/2020 MT Newswires

Ligand Pharmaceuticals (LGND) has an average analyst rating of buy, with an average price target of $165. Price: 94.61, Change: -12.94, Percent Change:...

View all Commentary and Analysis

Is the Options Market Predicting a Spike in Ligand (LGND) Stock?
9:51AM ET 4/09/2020 Zacks

Investors need to pay close attention to Ligand (LGND) stock based on the movements in the options...

XBI: Biotech ETF Expected To Outperform During And After The Coronavirus Pandemic
10:32AM ET 3/31/2020 Seeking Alpha

Ligand Pharmaceuticals (LGND) Presents At 32nd Annual ROTH Conference - Slideshow
3:41PM ET 3/17/2020 Seeking Alpha

Ligand Pharmaceuticals (LGND) Presents At Barclays Global Healthcare Conference - Slideshow
5:51PM ET 3/10/2020 Seeking Alpha

Company Profile

Business DescriptionLigand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA. View company web site for more details
Address3911 Sorrento Valley Boulevard
San Diego, California 92121
Phone+1.858.550.7500
Number of Employees116
Recent SEC Filing04/07/20208-K
Chief Executive Officer & DirectorJohn L. Higgins
President & Chief Operating OfficerMatthew William Foehr
Chief Financial Officer & EVP-FinanceMatthew Edward Korenberg
Vice President-Preclinical Research & DevelopmentEric Vajda

Company Highlights

Price Open$84.31
Previous Close$83.01
52 Week Range$57.24 - 130.50
Market Capitalization$1.4 B
Shares Outstanding16.5 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement05/06/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings2.50
Earnings per Share$29.17
Beta vs. S&P 500N/A
Revenue$251.5 M
Net Profit Margin523.19%
Return on Equity67.32%

Analyst Ratings as of 03/23/2020

Buy
6
Overweight
0
Hold
2
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset